RecruitingFemale onlyEN originalBreast cancer

A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

Through the research of this project, we expect to validate the clinical utility of the TuFEst-LN model in assessing axillary lymph node status in breast cancer patients. Specifically, we aim to prospectively validate its ability to identify pathologically node-negative patients among clinically and radiologically assessed cN0 patients undergoing upfront surgery ,and explore the predictive value of the TuFEst-LN model combined with preoperative MRI for ypN status assessment in initially node-positive patients following neoadjuvant therapy.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Potwierdzony histologicznie inwazyjny rak piersi
  • Guz wielkości T1-3 bez widocznych przerzutów do węzłów chłonnych i na odległość
  • Brak podejrzanych węzłów chłonnych w badaniu fizykalnym
  • Brak podejrzanych węzłów chłonnych w badaniach obrazowych (ultradźwięk)
  • Jeśli węzły były podejrzane, to biopsja wykazała brak nowotworu
  • Brak poprzedniego leczenia chemioterapią, hormonalną lub radioterapią
  • Planowana operacja piersi z biopsją węzła strażnika i/lub usunięciem węzłów chłonnych
  • Możliwość pobrania próbki krwi do badania przed operacją

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
August 10, 2026
Sex
Female only

Therapies / drugs in trial

Locations (1)

Second affiliated hospital of Medical school, Zhejiang university

Hangzhou, China

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.